SIBP-A10

Phase 1Small molecule

SShanghai Institute Of Biological Products

SIBP-A10 is one of 2 small molecule programs targeting Malignant Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant TumorRecruiting

Malignant TumorPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Malignant Tumor

#DrugCompanyPhaseTrials

JS207

SShanghai Junshi Bioscience Co., Ltd.

Phase 1

1 2

SIBP-A10

SShanghai Institute Of Biological Products

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Malignant Tumor

NCT07205198

Clinical

Trials by Indication[1]

Malignant Tumor1 trial

A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.

Recruiting·SShanghai Institute Of Biological Products·Phase 1·NCT07205198·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SIBP-A10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SIBP-A10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SIBP-A10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Institute Of Biological Products company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai Institute Of Biological Products

SIBP-A10

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Malignant Tumor1 trial

References

Drug Info

Quick Facts

Related News